Direct Conversion of Arylamines to the Halides by Deamination with Thionitrite or Related Compounds and Anhydrous Copper(II) Halides
作者:Shigeru Oae、K\={o}ichi Shinhama、Yong Hae Kim
DOI:10.1246/bcsj.53.1065
日期:1980.4
Reactions of various arylamines with either t-butyl thionitrite, t-butyl thionitrate, or p-toluenesulfonyl nitrite in the presence of anhydrous copper(II) halides under mild conditions gave corresponding aryl halides in good yields. This reaction in the presence of such olefins as acrylonitrile, styrene, and acrylic acid gave the corresponding 2-aryl-1-haloethanes as the main products. t-Butyl thionitrite
在无水卤化铜 (II) 存在下,各种芳基胺与亚硫硝酸叔丁酯、亚硫硝酸叔丁酯或对甲苯磺酰亚硝酸酯在温和条件下反应,以良好的收率得到相应的芳基卤化物。在丙烯腈、苯乙烯和丙烯酸等烯烃存在下,该反应得到相应的 2-芳基-1-卤代乙烷作为主要产物。由于硫-氮键较弱,亚硝酸叔丁酯、亚硝酸叔丁酯和对甲苯磺酰亚硝酸酯是比亚硝酸烷基酯或硝酸烷基酯更好的脱氨基试剂。
Reductive deimination of sulfoximides and sulfilimides with p-toluenesulfonyl nitrite, a new nitrosating agent
作者:Shigeru Oae、Kazuyuki Iida、Toshikazu Takata
DOI:10.1016/s0040-4039(01)90158-3
日期:——
Reductive deiminations of diaryl sulfilimides and dialkyl and aryl alkyl sulfoximides with p-toluenesulfonyl nitrite, a new nitrosatingreagent, has been investigated.
Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
申请人:Avista Pharma Solutions, Inc.
公开号:US10239885B1
公开(公告)日:2019-03-26
The present invention describes novel compounds, or veterinary or pharmaceutically acceptable salts thereof, veterinary or pharmaceutical compositions thereof, and medical uses thereof. The compounds of the invention have activity as prostaglandin EP4 receptor antagonists and are useful in the treatment or alleviation of pain, inflammation and inflammation-associated disorders. Also described herein are methods for treating pain by administering the compounds of the invention. For example, the invention describes 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-a]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyflurea of the formula:
veterinary or pharmaceutical compositions thereof, and methods of treatment using the subject compound and compositions thereof.
[EN] CB RECEPTOR AGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS CB
申请人:IRONWOOD PHARMACEUTICALS INC
公开号:WO2011006066A1
公开(公告)日:2011-01-13
The present disclosure relates to compounds of formula I useful as agonists of cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders.
The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.